CREMOLINI, CHIARA Statistiche
CREMOLINI, CHIARA
DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO).
2012-01-01 Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
2018-01-01 Cremolini, C; Antoniotti, Carlotta; Lonardi, S; Aprile, G; Bergamo, F; Masi, G; Grande, R; Tonini, G; Mescoli, C; Cardellino, Gg; Coltelli, L; Salvatore, Lisa; Corsi, Dc; Lupi, C; Gemma, D; Ronzoni, M; Dell'Aquila, E; Marmorino, F; Di Fabio, F; Mancini, Ml; Marcucci, L; Fontanini, G; Zagonel, V; Boni, L; Falcone, A
Advanced nanotechnology for enhancing immune checkpoint blockade therapy
2021-01-01 Cremolini, C.; Vitale, E.; Rastaldo, R.; Giachino, C.
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer
2017-01-01 Pietrantonio, F; Di Nicolantonio, F; Schrock, Ab; Lee, J; Tejpar, S; Sartore Bianchi, A; Hechtman, Jf; Christiansen, J; Novara, L; Tebbutt, N; Fucà, G; Antoniotti, Carlotta; Kim, St; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, B; Stephens, Pj; Chen, M; Cremolini, Chiara
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
2018-01-01 Pietrantonio, Filippo; Di Nicolantonio, Federica; Schrock, Alexa B; Lee, Jeeyun; Tejpar, Sabine; Sartore-Bianchi, Andrea; Hechtman, Jaclyn F; Christiansen, Jason; Novara, Luca; Tebbutt, Niall; Fucà, Giovanni; Antoniotti, Carlotta; Kim, Seung Tae; Murphy, Danielle; Berenato, Rosa; Morano, Federica; Sun, James; Min, Bosun; Stephens, Philip J; Chen, Marissa; Cremolini, Chiara
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in K-RAS wild-type metastatic colorectal cancer (mCRC) patients
2009-01-01 F., Loupakis; Cremolini, Chiara; G., Perrone; I., Stasi; L., Salvatore; B., Vincenzi; A., Ruzzo; M., Ronzoni; K., Bencardino; Falcone, Alfredo
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3
2019-01-01 Tokunaga, Ryuma; Cao, Shu; Naseem, Madiha; Battaglin, Francesca; Lo, Jae Ho; Arai, Hiroyuki; Loupakis, Fotios; Stintzing, Sebastian; Puccini, Alberto; Berger, Martin D; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Salhia, Bodour; Mumenthaler, Shannon M; Weisenberger, Daniel J; Liang, Gangning; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo; Millstein, Joshua; Lenz, Heinz-Josef
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
2012-01-01 Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, C; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, A; Danesi, R
AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS.
2012-01-01 Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, Alfredo; Danesi, Romano
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).
2013-01-01 Schirripa, M; Loupakis, F; Cremolini, Chiara; Morvillo, M; Bergamo, F; Zoratto, F; Salvatore, L; Antoniotii, C; Marmorino, F; Sensi, E; Lupi, C; Fontanini, Gabriella; DE GREGORIO, V; Giannini, R; Basolo, F; Masi, G; Falcone, Alfredo
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
2020-01-01 Dell'Aquila, E.; Zeppola, T.; Stellato, M.; Pantano, F.; Scartozzi, M.; Madaudo, C.; Pietrantonio, F.; Cremolini, C.; Aprile, G.; Vincenzi, B.; Moretto, R.; Puzzoni, M.; Garattini, S. K.; Lobefaro, R.; Tonini, G.; Santini, D.
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
2022-01-01 Fuca, G.; Cohen, R.; Lonardi, S.; Shitara, K.; Elez, M. E.; Fakih, M.; Chao, J.; Klempner, S. J.; Emmett, M.; Jayachandran, P.; Bergamo, F.; Garcia, M. D.; Mazzoli, G.; Provenzano, L.; Colle, R.; Svrcek, M.; Ambrosini, M.; Randon, G.; Shah, A. T.; Salati, M.; Fenocchio, E.; Salvatore, L.; Chida, K.; Kawazoe, A.; Conca, V.; Curigliano, G.; Corti, F.; Cremolini, C.; Overman, M.; Andre, T.; Pietrantonio, F.
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
2009-01-01 A., Ruzzo; Cremolini, Chiara; F., Loupakis; L., Fornaro; D., Santini; B., Vincenzi; E., Canestrari; M., Magnani; Falcone, Alfredo; F., Graziano
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
2020-01-01 Antoniotti, C.; Borelli, B.; Rossini, D.; Pietrantonio, F.; Morano, F.; Salvatore, L.; Lonardi, S.; Marmorino, F.; Tamberi, S.; Corallo, S.; Tortora, G.; Bergamo, F.; Brunella, D. S.; Boccaccino, A.; Grassi, E.; Racca, P.; Tamburini, E.; Aprile, G.; Moretto, R.; Boni, L.; Falcone, A.; Cremolini, C.
atypical RAS mutations in metastatic colorectal cancer
2019-01-01 Pietrantonio, F; Yaeger, R; Scrock, Ab; Randon, G; Romero-Cordoba, S; Rossini, D; Fucà, G; Ross, Js; Kotani, D; Madison, R; Kim, St; Salvatore, L; Raimondi, A; Pagani, F; Borelli, B; Perrone, F; Di, Bartolomeo; Miller, Va; Ali, Sm; Lee, J; Yoshino, T; de Braud, F; Falcone, A; Hechtman, Jf; Cremolini, C
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers (Scientific Reports, (2019), 9, 1, (3545), 10.1038/s41598-019-40310-5)
2020-01-01 Volpi, C. C.; Pietrantonio, F.; Gloghini, A.; Fuca, G.; Giordano, S.; Corso, S.; Pruneri, G.; Antista, M.; Cremolini, C.; Fasano, E.; Saggio, S.; Faraci, S.; Di Bartolomeo, M.; de Braud, F.; Di Nicola, M.; Tagliabue, E.; Pupa, S. M.; Castagnoli, L.
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
2017-01-01 Berger, Martin D; Yamauchi, Shinichi; Cao, Shu; Hanna, Diana L.; Sunakawa, Yu; Schirripa, Marta; Matsusaka, Satoshi; Yang, Dongyun; Groshen, Susan; Zhang, Wu; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Lonardi, Sara; Cremolini, Chiara; Falcone, Alfredo; Heinemann, Volker; Loupakis, Fotios; Stintzing, Sebastian; Lenz, Heinz Josef
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
2020-01-01 Cardone, C.; Blauensteiner, B.; Moreno-Viedma, V.; Martini, G.; Simeon, V.; Vitiello, P. P.; Ciardiello, D.; Belli, V.; Matrone, N.; Troiani, T.; Morgillo, F.; Zito Marino, F.; Dentice, M.; Nappi, A.; Boccaccino, A.; Antoniotti, C.; Cremolini, C.; Pietrantonio, F.; Prager, G. W.; Normanno, N.; Maiello, E.; Argiles, G.; Elez, E.; Signoriello, G.; Franco, R.; Falcone, A.; Tabernero, J.; Sibilia, M.; Ciardiello, F.; Martinelli, E.
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study
2019-01-01 Cremolini, Chiara; Benelli, Matteo; Fontana, Elisa; Pagani, Filippo; Rossini, Daniele; Fucà, Giovanni; Busico, Adele; Conca, Elena; Di Donato, Samantha; Loupakis, Fotios; Schirripa, Marta; Lonardi, Sara; Borelli, Beatrice; Ongaro, Elena; Eason, Katherine; Morano, Federica; Casagrande, Mariaelena; Fassan, Matteo; Sadanandam, Anguraj; De Braud, Filippo; Falcone, Alfredo; Pietrantonio, Filippo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). | 1-gen-2012 | Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo | |
| Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. | 1-gen-2018 | Cremolini, C; Antoniotti, Carlotta; Lonardi, S; Aprile, G; Bergamo, F; Masi, G; Grande, R; Tonini, G; Mescoli, C; Cardellino, Gg; Coltelli, L; Salvatore, Lisa; Corsi, Dc; Lupi, C; Gemma, D; Ronzoni, M; Dell'Aquila, E; Marmorino, F; Di Fabio, F; Mancini, Ml; Marcucci, L; Fontanini, G; Zagonel, V; Boni, L; Falcone, A | |
| Advanced nanotechnology for enhancing immune checkpoint blockade therapy | 1-gen-2021 | Cremolini, C.; Vitale, E.; Rastaldo, R.; Giachino, C. | |
| ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer | 1-gen-2017 | Pietrantonio, F; Di Nicolantonio, F; Schrock, Ab; Lee, J; Tejpar, S; Sartore Bianchi, A; Hechtman, Jf; Christiansen, J; Novara, L; Tebbutt, N; Fucà, G; Antoniotti, Carlotta; Kim, St; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, B; Stephens, Pj; Chen, M; Cremolini, Chiara | |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer | 1-gen-2018 | Pietrantonio, Filippo; Di Nicolantonio, Federica; Schrock, Alexa B; Lee, Jeeyun; Tejpar, Sabine; Sartore-Bianchi, Andrea; Hechtman, Jaclyn F; Christiansen, Jason; Novara, Luca; Tebbutt, Niall; Fucà, Giovanni; Antoniotti, Carlotta; Kim, Seung Tae; Murphy, Danielle; Berenato, Rosa; Morano, Federica; Sun, James; Min, Bosun; Stephens, Philip J; Chen, Marissa; Cremolini, Chiara | |
| Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in K-RAS wild-type metastatic colorectal cancer (mCRC) patients | 1-gen-2009 | F., Loupakis; Cremolini, Chiara; G., Perrone; I., Stasi; L., Salvatore; B., Vincenzi; A., Ruzzo; M., Ronzoni; K., Bencardino; Falcone, Alfredo | |
| AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 | 1-gen-2019 | Tokunaga, Ryuma; Cao, Shu; Naseem, Madiha; Battaglin, Francesca; Lo, Jae Ho; Arai, Hiroyuki; Loupakis, Fotios; Stintzing, Sebastian; Puccini, Alberto; Berger, Martin D; Soni, Shivani; Zhang, Wu; Mancao, Christoph; Salhia, Bodour; Mumenthaler, Shannon M; Weisenberger, Daniel J; Liang, Gangning; Cremolini, Chiara; Heinemann, Volker; Falcone, Alfredo; Millstein, Joshua; Lenz, Heinz-Josef | |
| An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients | 1-gen-2012 | Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, C; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, A; Danesi, R | |
| AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS. | 1-gen-2012 | Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, Alfredo; Danesi, Romano | |
| Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). | 1-gen-2013 | Schirripa, M; Loupakis, F; Cremolini, Chiara; Morvillo, M; Bergamo, F; Zoratto, F; Salvatore, L; Antoniotii, C; Marmorino, F; Sensi, E; Lupi, C; Fontanini, Gabriella; DE GREGORIO, V; Giannini, R; Basolo, F; Masi, G; Falcone, Alfredo | |
| Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? | 1-gen-2020 | Dell'Aquila, E.; Zeppola, T.; Stellato, M.; Pantano, F.; Scartozzi, M.; Madaudo, C.; Pietrantonio, F.; Cremolini, C.; Aprile, G.; Vincenzi, B.; Moretto, R.; Puzzoni, M.; Garattini, S. K.; Lobefaro, R.; Tonini, G.; Santini, D. | |
| Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers | 1-gen-2022 | Fuca, G.; Cohen, R.; Lonardi, S.; Shitara, K.; Elez, M. E.; Fakih, M.; Chao, J.; Klempner, S. J.; Emmett, M.; Jayachandran, P.; Bergamo, F.; Garcia, M. D.; Mazzoli, G.; Provenzano, L.; Colle, R.; Svrcek, M.; Ambrosini, M.; Randon, G.; Shah, A. T.; Salati, M.; Fenocchio, E.; Salvatore, L.; Chida, K.; Kawazoe, A.; Conca, V.; Curigliano, G.; Corti, F.; Cremolini, C.; Overman, M.; Andre, T.; Pietrantonio, F. | |
| Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients | 1-gen-2009 | A., Ruzzo; Cremolini, Chiara; F., Loupakis; L., Fornaro; D., Santini; B., Vincenzi; E., Canestrari; M., Magnani; Falcone, Alfredo; F., Graziano | |
| AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer | 1-gen-2020 | Antoniotti, C.; Borelli, B.; Rossini, D.; Pietrantonio, F.; Morano, F.; Salvatore, L.; Lonardi, S.; Marmorino, F.; Tamberi, S.; Corallo, S.; Tortora, G.; Bergamo, F.; Brunella, D. S.; Boccaccino, A.; Grassi, E.; Racca, P.; Tamburini, E.; Aprile, G.; Moretto, R.; Boni, L.; Falcone, A.; Cremolini, C. | |
| atypical RAS mutations in metastatic colorectal cancer | 1-gen-2019 | Pietrantonio, F; Yaeger, R; Scrock, Ab; Randon, G; Romero-Cordoba, S; Rossini, D; Fucà, G; Ross, Js; Kotani, D; Madison, R; Kim, St; Salvatore, L; Raimondi, A; Pagani, F; Borelli, B; Perrone, F; Di, Bartolomeo; Miller, Va; Ali, Sm; Lee, J; Yoshino, T; de Braud, F; Falcone, A; Hechtman, Jf; Cremolini, C | |
| Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers (Scientific Reports, (2019), 9, 1, (3545), 10.1038/s41598-019-40310-5) | 1-gen-2020 | Volpi, C. C.; Pietrantonio, F.; Gloghini, A.; Fuca, G.; Giordano, S.; Corso, S.; Pruneri, G.; Antista, M.; Cremolini, C.; Fasano, E.; Saggio, S.; Faraci, S.; Di Bartolomeo, M.; de Braud, F.; Di Nicola, M.; Tagliabue, E.; Pupa, S. M.; Castagnoli, L. | |
| Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials | 1-gen-2017 | Berger, Martin D; Yamauchi, Shinichi; Cao, Shu; Hanna, Diana L.; Sunakawa, Yu; Schirripa, Marta; Matsusaka, Satoshi; Yang, Dongyun; Groshen, Susan; Zhang, Wu; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Lonardi, Sara; Cremolini, Chiara; Falcone, Alfredo; Heinemann, Volker; Loupakis, Fotios; Stintzing, Sebastian; Lenz, Heinz Josef | |
| AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer | 1-gen-2020 | Cardone, C.; Blauensteiner, B.; Moreno-Viedma, V.; Martini, G.; Simeon, V.; Vitiello, P. P.; Ciardiello, D.; Belli, V.; Matrone, N.; Troiani, T.; Morgillo, F.; Zito Marino, F.; Dentice, M.; Nappi, A.; Boccaccino, A.; Antoniotti, C.; Cremolini, C.; Pietrantonio, F.; Prager, G. W.; Normanno, N.; Maiello, E.; Argiles, G.; Elez, E.; Signoriello, G.; Franco, R.; Falcone, A.; Tabernero, J.; Sibilia, M.; Ciardiello, F.; Martinelli, E. | |
| Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study | 1-gen-2019 | Cremolini, Chiara; Benelli, Matteo; Fontana, Elisa; Pagani, Filippo; Rossini, Daniele; Fucà, Giovanni; Busico, Adele; Conca, Elena; Di Donato, Samantha; Loupakis, Fotios; Schirripa, Marta; Lonardi, Sara; Borelli, Beatrice; Ongaro, Elena; Eason, Katherine; Morano, Federica; Casagrande, Mariaelena; Fassan, Matteo; Sadanandam, Anguraj; De Braud, Filippo; Falcone, Alfredo; Pietrantonio, Filippo |